Imatinib Induces Up-regulation of NM23, a metastasis suppressor gene, in human Hepatocarcinoma (HepG2) Cell Line

Behta Keshavarz-Pakseresht1, Seyed Ataollah Sadat Shandiz2, Fahimeh Baghbani-arani1
1 Department of Genetics and Biotechnology, School of Biological Science, Varamin-Pishva Branch, Islamic Azad University, Varamin, Iran
2 Young Researchers and Elite Club, East Tehran Branch, Islamic Azad University, Tehran, Iran

Abstract

Aim: The present study investigated the anti-tumor activity of Imatinib mesylate through modulation of NM23 gene expression in human hepatocellular carcinoma (HepG2) cell line.

Background: Hepatocellular carcinoma (HCC) is considered to be the third leading cause of cancer related death worldwide. Down regulation of NM23, a metastasis suppressor gene, has been associated with several types of malignant cancer. Recently, effects of Imatinib mesylate, a first member of tyrosine kinases inhibitors, were indicated in research and treatment of different malignant tumors.

Methods: Cell viability was quantitated by MTT assay after HepG2 cells exposure to Imatinib mesylate at various concentrations of 0, 1.56, 3.125, 6.25, 12.5, 25,50μM for 24 hours. Also, quantitative real time PCR technique was applied for the detection of NM23 gene expression in HepG2 cell line.

Results: There was a dose dependent increase in the cytotoxicity effect of imatinib. The real time PCR results demonstrated that inhibitory effect of Imatinib mesylate on viability via up regulation of NM23 gene expression compared to GAPDH gene (internal control gene) in cancer cells.

Conclusion: According to our findings, imatinib can modulate metastasis by enhancing Nm23 gene expression in human hepatocellular carcinoma (HepG2) cell line.

Keywords: Imatinib mesylate, NM23, metastasis, HepG2.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers; where over 600000 deaths occur annually worldwide (1). Chemotherapy, radiation and surgical therapy have been used for the treatment of HCC. Although conventional chemotherapy remained the only therapeutic approach after surgery, its use has been toxic (2). Therefore, novel therapeutic strategies are urgently needed for more profitable treatment. Knowing about the gene expression alteration throughout tumor progression has been the subject of intense method for targeting metastatic cascade and inhibition of tumor progression. Currently, metastasis suppressor genes (MSGs) are found to be significant in the regulation of cell invasion and metastasis cascades (3). Non-metastatic protein (Nm23) is a nucleoside diphosphate kinase that is an exhibited interesting attribute with regard to metastasis. Several studies have confirmed that the reduced NM23 mRNA levels are related to different types of cancer cells with high metastatic potential (4, 5).

Recently, Molecular targeted therapy is designed to inhibit important signaling pathways included in metastasis and apoptosis. Different preclinical and clinical studies on molecular targeted therapies have demonstrated that it has great promise in the treatment of various malignant tumors (6). Tyrosine kinases Inhibitors (TKIs) are promising anticancer agents that often induce apoptosis and slow progression growth of bone metastases in tumor cells (7). Imatinib mesylate ( ST-571, Gleevec; Novartis Pharma), is the first member of new class of TKIs that acts by inhibiting specific tyrosine kinases like Bcr-Abl fusion oncoprotein in
chronic myeloid leukaemia (CML)(8), inhibits the activation of platelet-derived growth factor PDGF(ab) (9), c-Kit and is currently under evaluation in research and clinical trials for several solid tumors (10,11). Also, it was shown that imatinib can decrease the progressive growth and migratory properties of prostate and colorectal cancers and promote apoptosis in a number of cell lines such as glioblastoma, retinal ganglion, gastrointestinal stromal tumors and leukemic cells (12). The aim of the current study was to investigate the effect of Imatinib mesylate on cell viability and anti-cancer effect through modulation of NM23 gene expression in HepG2 human cell line.

Materials and Methods

Cell culture

The human hepatocellular carcinoma cell line HepG2 was obtained from the Pasteur Institute of Iran, Tehran. The cell line was grown in the Dulbecco’s Modified Eagle’s Medium (DMEM) medium supplemented with 10% fetal bovine serum (FBS), 100 unit/mL penicillin, 100μg/mL streptomycin in a 5% CO₂ atmosphere at 37 °C.

MTT assay

The degree of viability activity of Imatinib mesylate against HepG2 cancer cells was evaluated by 3-(4, 5-dimetheylthiazol)-2, 5-diphenyl tetrazolium bromide (MTT), assay. The grown cells at a density of 10,000 cells per well were seeded into 96-well microtiter plate and treated with different concentrations of Imatinib ranging from 0, 1.56, 3.125, 6.25, 12.5, 25 and 50μM. After incubation at 37°C for 24h, 10ml of the MTT solution (5 mg/ml in Phosphate Buffer Saline) was added to each well. The plate was incubated at 37 °C for 4 hours to further application. Afterward, the cell culture medium was discarded and 100μl of isopropanol (Merck, Germany) was added to the wells for dissolving the MTT formazan products. The optical density of each well was determined by measuring at 570nm with ELISA microplate reader (Organon Teknika, Netherlands). The optical density (OD) value was estimated to percentage of viability by the following formula: OD of treated cells/ OD of control cells ×100. The concentration that inhibits the activity by 50% (IC50) values of drug on HepG2 cells was evaluated using Graph-pad In Stat software.

Total RNA extraction and cDNA Synthesis

The HepG2 cell line was seeded into 6 well plates (5×10⁴ cells/well) and incubated for 24 hours. Then, cells were treated with Imatinib mesylate (within IC₅₀ dose) for 24 hours. According to the manufacturer’s instructions, total RNA was extracted using an RNA-isolation kit (Qiagen, RNeasy Plus Mini Kit 50). Complementary DNA synthesis was performed using commercially available kits (1st Synthesis Kit Roch, Germany) in a reaction mixture containing oligo dT Primer (50 μM), reaction Buffer 10x, MgCl₂ (25mM), dNTP mix (1mM), total RNA (1μg), AMV reverse transcriptase (20 units), RNase inhibitor (40 units) and nuclease-free water. The amplification step for the reverse transcription was measured by ABI 7700 Thermal Cycler (Applied Biosystems Company, California, USA) as follows: 30 °C for 10 minutes, 42 °C for 50 min and 95 °C for 5 min followed by cooling on ice for 5 min.

Quantitative analysis of gene expression by Real-time-PCR

The real time quantitative PCR was performed by an ABI 7300 real-time PCR system (Applied Biosystems company, USA) using SYBR Green PCR Master Mix according to the manufacturer’s protocol. Briefly, each quantitative PCR test was carried out in 25 μl total volume mixture including 12.5 μl of Power SYBR Green PCR Master Mix (2x), 5μl of cDNA sample (100 ng) 1 μl of each primer (0.4μM), final volume reach to 25ml with double-distilled water (5.5μl of DDW). This process began with following thermal-cycling conditions: 95 °C for 10min, 40 cycles were followed by 95 °C for 15 seconds and 60°C for 60 seconds. In the current study, Primer sequences corresponding to the genes were designed using Gene Runner software (version 3.05). Characteristics of the primers used in this study have been shown in Table 1. The specificity of desired primers was checked by utilizing the BLAST program (www.ncbi.nlm.nih.gov/blast).

The gene expression data was measured by using the comparative threshold cycle (Ct), the ΔCt value of NM23 gene was obtained by subtracting the Ct of target gene from reference gene Then, to obtain ΔΔCt value, the Dct of target gene was subtracted from Dct of reference; where ΔΔCt = [mCt NM23 – mCt GAPDH] (treated sample) - [mCt NM23 – mCt GAPDH] (untreated sample). Finally, the fold change in NM23 gene expression was calculated using the following

| Gene   | Primer sequence                                      |
|--------|------------------------------------------------------|
| NM23   | Forward: 5'- ATGGCCCAACTGTGAGCGTACC -3¢             |
|        | Revers: 5'- CATGTTATTTCAACCAGCCGCGC -3'             |
| GAPDH  | Forward: 5'- CGTCTGCCCTATCAACTTTTCG -3'             |
|        | Revers: 5'- CGTTTCTCAGGGCTCCCTCT -3'                |

Table 1. Characteristics of the Primers of NM23 and GAPDH genes used in the real time PCR assay
formula: (\text{Ratio formula}= 2^{-\Delta\Delta Ct}). The specificity of primer for amplification reactions was confirmed by melting curve analysis. Then, each real time PCR products were transferred into the well installed in 1.5% agarose gel in TBE and the fragments were visualized by ethidium bromide fluorescence method through trans-laminator system (UV dock, England).

**Statistical Analysis**

The statistical analyzes was calculated using SPSS statistical software version 22. The \(P\)-value of <0.05 data was considered statistically significant and was assessed using Student's \(t\)-test. All experimental data were done in triplicate and presented as the mean ± standard error.

**Results**

**MTT assay results**

Different concentrations of Imatinib mesylate had a cytotoxicity effect on HepG2 cancer cell line at 24h. At the concentration of 1.56, 3.125, 6.5, 12.5, 25, 50mM of Imatinib mesylate, the viability of HepG2 was reduced to 87.98±0.003, 84.92±0.002, 82.80± 0.01 (statistically insignificant, \(p>0.05\)), 59.15± 0.01(\(p<0.05\)), 30.10±0.007(\(p<0.05\)) and 6.7 ± 0.002% (\(p<0.001\)), respectively (Figure1). The mean viability percentage after the treatment with Imatinib was significantly decreased in HepG2 cells at a concentration of 25mM and higher. The IC\(_{50}\) of imatinib on hepatocellular carcinoma HepG2 was calculated 21.89mM for 24h.

**Melting curve analysis**

For quantitative gene expression analysis by Real-time-PCR, the melting curve plot was carried out based on \(dF/dT\) derivation (y axis) and the temperature (x axis). Our observation revealed a single product formation and screen for primer dimmers for each gene. The melting peaks have been drawn at 85.2°C for \(NM23\) gene and 86.5°C GAPDH gene as shown in Figure 2a. Moreover, gel electrophoresis results revealed the specific amplification of genes according to their sizes (Figure 2B).

**Relative quantification analysis using amplification plots**

The relative gene expression between untreated and treated samples can be measured by the difference in their Ct values of exponential phase. The mCt, mDcT and DDCt value for NM23 and GAPDH genes were evaluated in IC\(_{50}\) concentration of imatinib mesylate. The NM23/GAPDH gene expression ratio equals to 2\(^{-\Delta\Delta Ct}\). The expression of NM23 mRNA level was calculated 4.208±0.01 (statistically significant; \(p<0.01\)) in 21.89mM of Imatinib mesylate treatment compared to the control (Figure.3).

**Discussion**

Disturbance in the cell signaling pathways clearly has been studied in advanced HCC due to the resistance to therapy and progression of disease that causes the treatment choice limitation (13). Consequently, Tyrosine kinases Inhibitors are promising anti-cancer agents which often interfere with a specific molecular target in cell controlling signaling pathways in neoplastic cells (14, 15). These targets include modulators of apoptosis, cell-cycle proteins, growth factor receptors, and molecules involved in angiogenesis.

---

*Reference:*

Gastroenterol Hepatol Bed Bench 2017; 10 (1): 29–33
and invasion, which are important for homeostasis and development in normal tissues. Many studies have been reported the effect of Imatinib mesylate on several human solid tumors, including small cell lung cancer (16), thyroid cancer (14), and ovarian (17).

The use of Imatinib in the molecular targeting of cell signaling genes and proteins in HCC cells has not completely investigated to this point targeting the \textit{NM23} gene. In the current study, we demonstrated that Imatinib exerted a dose-dependent inhibitory effect on the viability of human hepatocellular carcinoma HepG2 cell line. Treatment of HepG2 with Imatinib induced the morphological changes that verify the expansion in apoptotic cell population. Most cancer mortalities are induced by the progression of tumor metastasis; hence the most important contributor to cancer related morbidity and mortality (18, 19).

Identification of the gene expression during tumor progression has been the great significant of intense method for prognosis and therapy. The amount of \textit{NM23} gene expression has a significant role in targeting tumor metastasis. Loss of \textit{NM23} expression has been correlated with the degree of metastasis and undesirable clinical prognosis in various types of human carcinoma (18). Also, it has been demonstrated that the NM23 protein is participated in the regulation of several cellular responses such as differentiation, endocytosis, development, and apoptosis (20,21).

Several researchers claim that there is an important relation between reduced expression of \textit{NM23} and the occurrence of metastasis in breast cancer, malignant melanoma, gastric cancer and hepatocellular cancers while there is completely opposite in case of adenocarcinoma of the lung, neuroblastoma. In 1995, Lin, \textit{et al.} reported correlation between high \textit{in vitro} invasive capacity and a low NM23 protein level when analyzing eight human liver cancer cells (22). Fujimoto, \textit{et al.} (1998) observed that the nm23 protein level was obviously decreased in poorly differentiated HCC cell lines, HuH-1 and HuH-2 and the hepatocarcinoma cell line, HepG-2 (23). In 1994 yamaguchi \textit{et al} reported that \textit{NM23} expression was conversely related to metastasis potential of HCC (24). Recently, it has been reported that the alteration of P53 tumor suppressor gene and down regulation of \textit{NM23} gene are both more prone to metastasis (21). The interaction between P53 and Nm23 may lead to cell cycle arrest and apoptosis. It has been demonstrated the NM23 protein with STRAP (serine threonine kinase receptor associated protein) promotes the association between p53 and NM23, resulting in the apoptosis and cell cycle arrest (21). The consequential finding in our study was indicating that Imatinib can up-regulate \textit{NM23} gene expression in human hepatocellular carcinoma HepG2 cell line which has not yet been studied. To the best of our knowledge, increased expression of \textit{NM23} was changed significantly 4.20 fold at IC\textsubscript{50} of Imatinib concentration respect to control gene. Therefore, Imatinib mesylate remains a promising candidate for the treatment of hepatocellular carcinoma in the future.

\textbf{Conclusion}

In this study, we demonstrated that treatment with imatinib for 24 h induces a dose-dependent inhibitory manner on the HepG2 cell line. Also, imatinib mesylate induces up
regulation of NM23 expression, metastasis suppressor gene, in hepatocellular carcinoma HepG2 cells. Thus, for a definitive conclusion, imatinib may be a good candidate for utilization as an inhibitor of the growth of other cancer cell lines as well as in vivo animal tumor models.

Acknowledgements

The authors would like to acknowledge the Radio-pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, for contribution in the experimental works.

Conflict of Interest

No conflict of interest to declare

References

1. Saad Zaghloul MA, Abadi AH, Abdelaziz AJ. Functional evolution of imatinib mesylate in hepatocellular carcinoma cells. Recent Pat Biomark 2013; 3: 65-71.

2. Marin JLG, Castano B, Martinez Becerra P, Rosales R, Monte MJ. Chemotherapy in the treatment of primary liver tumors. Cancer Ther 2008; 6:711-28.

3. Buxton ILO, Yokdang N. Extracellular Nm23 Signaling in breast cancer: incommodus verum. Cancers (Basel) 2011; 3: 2844-57.

4. Howlett AR, Petersen OW, Steeg PS, Bissell MJ. A novel function for the nm23-H1 gene: overexpression in human breast carcinoma cells leads to the formation of basement membrane and growth arrest. J Natl Cancer Inst 2010; 86: 1838-44.

5. Shangyang S, Xu B, He M, Lan X, Wang Q. Nm23-H1 suppresses hepatocarcinoma cell adhesion and migration on fibronectin by modulating glycosylation of integrin beta1. J Exp Clin Cancer Res 2010; 29: 93.

6. Blay JY, Rutkowski P. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev 2014; 40: 242-7.

7. Sadat Shandiz SA, Shafiee Ardestani M, Irani S, Shahbazzadeh D. Imatinib induces down regulation of Bel-2 an anti-apoptotic protein in prostate cancer PC-3 cell line. Adv Stud Biol 2015; 7: 17-27.

8. Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, et al. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer 2010; 10: 412.

9. Bansa Sh. Is imatinib still the best choice as first-line oral TKI. South Asian J Cancer 2014; 3: 83-6.

10. Constance K, Woessner JE, Matussek DW, Mossalam KJ, Lim CS. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib. Mol Pharmacol 2012; 9: 3318-29.

11. Ronald Hassler M, Vedadinejad M, Flechl B, Haberler C, Preusser M, Andreas Hainfellner J, et al. Response to imatinib as a function of target kinase expression in recurrent glioblastoma. Springerplus 2014; 3: 111.

12. Ohishi J, Aoki M, Nabeshima K, Suzumiyia J, Takeuchi T, Ogose A, et al. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGF-b. BMC Cancer 2013; 13: 224.

13. Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 2009; 44: 136-41.

14. de Groot JW, Plaza Menacho I, Schepers H, Drenth-Diephuis LJ, Osinga J, Plukker JT, et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006; 139: 806-14.

15. Vogiatzi P, Cassone M, Claudio L, Claudio PP. Targeted therapy for advanced prostate cancer: Looking through new lenses. Drug News Prospect 2009; 22: 593-601.

16. Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, et al. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Int J Onco 2010; 37: 869-77.

17. Patil BB1, He YA, Li XM, Frolov A, Vanderveer L, Slater C, et al. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 2008; 5: 137-49.

18. Zhang Q, McCorkle JR, Novak M, Yang M, Kaetzel DM. Metastasis suppressor function of NM23-H1 requires its 30-50 exonuclease activity. Int J Cancer 2001; 128: 40-50.

19. Yoshioka BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: A review and perspective on an emerging field. J Natl Cancer Inst 2000; 92: 1717-30.

20. Jung S, Paek YW, Moon KS, Wee SC, Ryu HH, Jeong YL, et al. Expression of Nnm23 in gliomas and its effect on migration and invasion in vitro. Anticancer Res 2006; 26: 545-53.

21. Jung H, Seong HA. NM23-H1 tumor suppressor and its interacting partner STRAP activate p53 function. J Biol Chem 2007; 30: 32923-307.

22. Lin KH, Lin YW, Lee HF, Liu WL, Chen ST, Chang KS, et al. Increased invasive activity of human hepatocellular carcinoma cells is associated with an overexpression of thyroid hormone beta 1 nuclear receptor and low expression of the anti-metastatic nm23 gene. Cancer Lett 1995; 35293-307.

23. Fujimoto Y, Ohtake T, Nishimori H, Ikuta K, Ohira M, Ono M, et al. Reduced expression and rare genomic alteration of nm23-H1 in human hepatocellular carcinoma and hepatoma cell lines. J Gastroenterol 1998; 33: 568-75.

24. Yamaguchi A, Urano T, Gou T, Takeuchi K, Niimoto S, Nakagawara G, et al. Expression of human nm23-H1 and nm23-H2 proteins in hepatocellular carcinoma. Cancer 1994; 73: 2280-4 73: 2280-2284.